Sun Pharma shares in focus after $200 million settlement in US drug pricing case

Shares of Sun Pharma will be in focus after the company said its subsidiaries, SPII and Taro, have agreed to pay $200 million to settle an antitrust case in the US. The settlement, part of the ongoing generic drug pricing litigation, grants a full release from all claims filed by End Purchaser Plaintiffs against the firms and their affiliates.